אוסטרליה - אנגלית - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - pertuzumab, quantity: 420 mg - injection, intravenous infusion - excipient ingredients: histidine; sucrose; glacial acetic acid; water for injections; polysorbate 20 - early breast cancer perjeta is indicated in combination with trastuzumab and chemotherapy for:,- the neoadjuvant treatment of patients with her2-positive inflammatory or locally advanced, or early stage (either > 2 cm in diameter or node positive) breast cancer as part of a complete treatment regimen for early breast cancer,-the adjuvant treatment of patients with her2-positive early breast cancer at high risk of recurrence.,metastatic breast cancer,perjeta is indicated in combination with trastuzumab and docetaxel for patients with metastatic her2-positive breast cancer who have not received prior anti-her2 therapy or chemotherapy for their metastatic disease.